XTX Topco Ltd Sells 17,892 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

XTX Topco Ltd reduced its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 56.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 13,890 shares of the company’s stock after selling 17,892 shares during the period. XTX Topco Ltd’s holdings in Xeris Biopharma were worth $40,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC bought a new position in shares of Xeris Biopharma in the third quarter valued at approximately $35,000. Quantbot Technologies LP acquired a new stake in Xeris Biopharma during the 3rd quarter valued at $44,000. Allspring Global Investments Holdings LLC increased its holdings in Xeris Biopharma by 4,512.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock valued at $37,000 after purchasing an additional 15,929 shares in the last quarter. Asset Management Group Inc. raised its position in Xeris Biopharma by 130.7% in the 2nd quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock valued at $60,000 after purchasing an additional 15,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Xeris Biopharma by 64.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 28,657 shares of the company’s stock worth $82,000 after purchasing an additional 11,239 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Monday, November 11th. HC Wainwright boosted their target price on shares of Xeris Biopharma from $6.00 to $6.60 and gave the stock a “buy” rating in a research note on Monday, November 11th.

Xeris Biopharma Stock Up 2.3 %

Shares of XERS opened at $3.49 on Monday. The stock’s fifty day simple moving average is $3.25 and its 200-day simple moving average is $2.78. The firm has a market capitalization of $520.29 million, a PE ratio of -7.76 and a beta of 2.65. Xeris Biopharma Holdings, Inc. has a 12-month low of $1.69 and a 12-month high of $3.87.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.